ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.356,75
-0,17%
S&P 500
6.051,09
0,00%
Dow Jones
43.828,06
-0,20%
Euro vs US Dollar
1,05172
0,14%
Bitcoin
104.571,58
0,22%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. OS Therapies Incorporated (OSTX)

  7. OS Therapies Incorporated (OSTX) News

OSTX

OS Therapies (OSTX)

OS Therapies Incorporated
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:OSTX
DatumZeitQuelleÜberschriftSymbolFirma
15/11/202422h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
15/11/202415h47Business WireOS Therapies Reports Third Quarter 2024 Financial Results and Provides Business UpdateAMEX:OSTXOS Therapies Incorporated
15/11/202415h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:OSTXOS Therapies Incorporated
14/11/202422h58Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBAMEX:OSTXOS Therapies Incorporated
04/11/202413h00Business WireOS Therapies to Present at The Spartan Capital Investor ConferenceAMEX:OSTXOS Therapies Incorporated
01/11/202422h00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
30/10/202413h51Business WireJoin OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30AMEX:OSTXOS Therapies Incorporated
29/10/202421h10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
28/10/202421h55Edgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
28/10/202421h44Business WireOS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of DirectorsAMEX:OSTXOS Therapies Incorporated
24/10/202414h46Business WireOS Therapies to Present at the LD Micro Main Event XVIIAMEX:OSTXOS Therapies Incorporated
17/10/202415h22Business WireOS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitAMEX:OSTXOS Therapies Incorporated
03/10/202414h00Business WireOS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient VisitAMEX:OSTXOS Therapies Incorporated
13/09/202414h09Business WireOS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic CandidatesAMEX:OSTXOS Therapies Incorporated
05/09/202414h22Business WireOS Therapies to Present at H.C. Wainright 26th Annual Global Investment ConferenceAMEX:OSTXOS Therapies Incorporated
29/08/202413h53Business WireOS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment DoseAMEX:OSTXOS Therapies Incorporated
22/08/202414h00Business WireOS Therapies Appoints Borys Shor, PhD to ADC Advisory BoardAMEX:OSTXOS Therapies Incorporated
22/08/202412h00Business WireOS Therapies Clarifies CUSIP of Common StockAMEX:OSTXOS Therapies Incorporated
19/08/202414h30Business WireOS Therapies Accepted Into Johnson & Johnson Innovation - JLABSAMEX:OSTXOS Therapies Incorporated
02/08/202414h55Business WireOS Therapies Forms Osteosarcoma Patient Advocacy Advisory BoardAMEX:OSTXOS Therapies Incorporated
01/08/202415h19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
01/08/202415h16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
01/08/202415h11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
01/08/202415h10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
01/08/202415h08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
01/08/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:OSTXOS Therapies Incorporated
01/08/202400h21Business WireOS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”AMEX:OSTXOS Therapies Incorporated
30/07/202420h41Edgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingAMEX:OSTXOS Therapies Incorporated
30/07/202420h29Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]AMEX:OSTXOS Therapies Incorporated
24/07/202416h48Business WireOS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast CancerAMEX:OSTXOS Therapies Incorporated
 Showing the most relevant articles for your search:AMEX:OSTX

Kürzlich von Ihnen besucht

EU
FR001400NWM1
SG Issuer Sg Issuer Mc M...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten